NO20074063L - Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier - Google Patents

Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier

Info

Publication number
NO20074063L
NO20074063L NO20074063A NO20074063A NO20074063L NO 20074063 L NO20074063 L NO 20074063L NO 20074063 A NO20074063 A NO 20074063A NO 20074063 A NO20074063 A NO 20074063A NO 20074063 L NO20074063 L NO 20074063L
Authority
NO
Norway
Prior art keywords
psma
fucosyl residues
antibodies
monoclonal antibodies
antibodies against
Prior art date
Application number
NO20074063A
Other languages
English (en)
Inventor
Josephine M Cardarelli
David Passmore
Jenny Albanese
Lei Zhu
Original Assignee
Medarex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Llc filed Critical Medarex Llc
Publication of NO20074063L publication Critical patent/NO20074063L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SAMMENDRAG Oppfinnelsen angår anti-PSMA antistoffer som mangler fucosyl-rester. Antistoffene ifølge oppfinnelsen viser forøket antistoffavhengig cellulær cytotoksisitet (ADCC)-aktivitet sammenlignet med den fucosylerte formen av antistoffene. Oppfinnelsen tilveiebringer også vertsceller som uttrykker anti-PSMA antistoffene som mangler fucosyl-rester, hvor vertscellene mangler en fucosyltransferase. Fremgangmåter for anvendelse av antistoffene for å hemme veksten av PSMA+-celler, slik som tumorceller, tilveiebringes også.
NO20074063A 2005-02-18 2007-08-07 Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier NO20074063L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65426605P 2005-02-18 2005-02-18
US66043105P 2005-03-09 2005-03-09
PCT/US2006/005853 WO2006089231A2 (en) 2005-02-18 2006-02-17 Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues

Publications (1)

Publication Number Publication Date
NO20074063L true NO20074063L (no) 2007-11-13

Family

ID=36716634

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074063A NO20074063L (no) 2005-02-18 2007-08-07 Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier

Country Status (15)

Country Link
US (2) US7875278B2 (no)
EP (1) EP1851251A2 (no)
JP (1) JP5249587B2 (no)
KR (1) KR101291640B1 (no)
CN (1) CN101160324B (no)
AU (1) AU2006214032B2 (no)
BR (1) BRPI0607796A2 (no)
CA (1) CA2598454C (no)
IL (1) IL184949A0 (no)
MX (1) MX2007009935A (no)
NO (1) NO20074063L (no)
NZ (1) NZ560414A (no)
RU (1) RU2421466C2 (no)
WO (1) WO2006089231A2 (no)
ZA (1) ZA200707338B (no)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP1448588A4 (en) 2001-10-23 2006-10-25 Psma Dev Company L L C ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
US20060191026A1 (en) * 2005-02-18 2006-08-24 Origen Therapeutics, Inc. Tissue specific expression of antibodies in chickens
NZ556661A (en) * 2005-02-18 2010-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
BRPI0607796A2 (pt) * 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20080279868A1 (en) * 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
JP2009514814A (ja) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
EP2486941B1 (en) 2006-10-02 2017-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
JP2009082033A (ja) * 2007-09-28 2009-04-23 Kaneka Corp 完全ヒト型抗体生産法
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
EP2311493A4 (en) * 2008-05-20 2012-09-26 Kaneka Corp CYTOTOXIC COMPOSITION
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2438495T3 (es) 2008-09-08 2014-01-17 Psma Development Company, L.L.C. Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano
WO2011008517A2 (en) * 2009-06-30 2011-01-20 Research Development Foundation Immunoglobulin fc polypeptides
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011019844A1 (en) 2009-08-13 2011-02-17 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal cdrs
JP6077856B2 (ja) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
US8865462B2 (en) 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
KR101835474B1 (ko) * 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 항바이러스 화합물
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US9891224B2 (en) 2012-01-30 2018-02-13 The Johns Hopkins University Biomarkers for aggressive prostate cancer
PE20142406A1 (es) * 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
EP3536700A1 (en) 2012-06-07 2019-09-11 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2887047A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
LT2839860T (lt) 2012-10-12 2019-07-10 Medimmune Limited Pirolobenzodiazepinai ir jų konjugatai
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
KR20150093834A (ko) 2012-12-13 2015-08-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｄｎａ 항체 작제물 및 그 이용 방법
SG11201506243XA (en) 2013-02-14 2015-09-29 Bristol Myers Squibb Co Tubulysin compounds, methods of making and use
BR112015023333A8 (pt) 2013-03-13 2018-04-17 Medimmune Ltd pirrolbenzodiazepinas e conjugados dos mesmos
EA201690388A1 (ru) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
HUE043875T2 (hu) * 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CA2963470A1 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
CA2969214A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
KR20230137502A (ko) 2014-12-19 2023-10-04 레제네상스 비.브이. 인간 c6에 결합하는 항체 및 이의 용도
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
EP3256490A1 (en) 2015-02-09 2017-12-20 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
MX2017011600A (es) * 2015-03-10 2018-06-13 Sorrento Therapeutics Inc Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
MX2018007479A (es) 2015-12-21 2018-08-01 Squibb Bristol Myers Co Anticuerpos variantes para conjugacion especifica de sitio.
KR102302973B1 (ko) 2016-01-29 2021-09-16 효성티앤씨 주식회사 투명성이 높은 비결정성 폴리에틸렌테레프탈레이트 중합물의 제조방법
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
CN109071637B (zh) * 2016-03-23 2022-03-22 首尔大学校产学协力团 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途
CA3056374A1 (en) * 2016-04-13 2017-10-19 Orimabs Ltd. Anti-psma antibodies and use thereof
US11104739B2 (en) 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
CN109069665A (zh) 2016-05-10 2018-12-21 百时美施贵宝公司 具有增强的稳定性的微管溶素类似物的抗体-药物缀合物
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
CN109641911B (zh) 2016-08-19 2023-02-21 百时美施贵宝公司 seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
US11267873B2 (en) 2016-10-13 2022-03-08 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
DE102016221494A1 (de) 2016-11-02 2018-05-03 Bsn Medical Gmbh Débridement-Vorrichtung
JP7039582B2 (ja) 2016-11-03 2022-03-22 ブリストル－マイヤーズ スクイブ カンパニー 活性化可能な抗ｃｔｌａ－４抗体およびその使用
WO2018160536A1 (en) 2017-02-28 2018-09-07 Bristol-Myers Squibb Company Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP3630833A1 (en) 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
EA202092747A1 (ru) 2018-05-29 2021-03-16 Бристол-Маерс Сквибб Компани Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
EP3849608B1 (en) 2018-09-13 2023-08-30 The Board of Regents of The University of Texas System Novel lilrb4 antibodies and uses thereof
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
ES2943474T3 (es) 2018-11-30 2023-06-13 Bristol Myers Squibb Co Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN113924118A (zh) 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
US20230075422A1 (en) 2019-12-20 2023-03-09 Bristol-Myers Squibb Company Use of fucosylation inhibitor for producing afucosylated antibody
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CA3169479A1 (en) 2020-02-27 2021-09-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
AU2021271960A1 (en) 2020-05-12 2023-02-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ST2 antigen binding protein
JP7554292B2 (ja) 2020-06-25 2024-09-19 メルク・シャープ・アンド・ドーム・エルエルシー セリン４１３においてリン酸化されたタウを標的化する高親和性抗体
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
EP4240769A1 (en) 2020-11-06 2023-09-13 Bristol-Myers Squibb Company Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4337700A1 (en) * 2021-05-12 2024-03-20 Technische Universität München Humanized anti-psma antibody
KR20240025597A (ko) 2021-06-29 2024-02-27 씨젠 인크. 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
CN118159286A (zh) 2021-11-25 2024-06-07 正大天晴药业集团股份有限公司 抗Siglec-15抗体及其应用
WO2024031032A1 (en) 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577292A (en) * 1897-02-16 Puzzle
US5153118A (en) * 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
DE3684578D1 (de) 1985-12-17 1992-04-30 Eastern Virginia Medical Autho Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
US7105159B1 (en) * 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
EP0668777B2 (en) * 1992-11-05 2011-02-09 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
AU717937B2 (en) 1995-02-24 2000-04-06 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
WO1997035616A1 (en) 1996-03-25 1997-10-02 Pacific Northwest Cancer Foundation Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
CA2704600C (en) * 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
CN100589845C (zh) 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
EP1448588A4 (en) * 2001-10-23 2006-10-25 Psma Dev Company L L C ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
AU2003224604B2 (en) * 2002-01-28 2007-06-14 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
AU2003236015A1 (en) * 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica

Also Published As

Publication number Publication date
KR20070104665A (ko) 2007-10-26
MX2007009935A (es) 2007-10-10
CA2598454C (en) 2013-04-09
US7875278B2 (en) 2011-01-25
EP1851251A2 (en) 2007-11-07
CA2598454A1 (en) 2006-08-24
JP5249587B2 (ja) 2013-07-31
CN101160324B (zh) 2013-04-24
IL184949A0 (en) 2007-12-03
WO2006089231A2 (en) 2006-08-24
BRPI0607796A2 (pt) 2009-06-13
WO2006089231A3 (en) 2006-12-07
KR101291640B1 (ko) 2013-08-05
JP2008530243A (ja) 2008-08-07
CN101160324A (zh) 2008-04-09
AU2006214032B2 (en) 2012-03-08
NZ560414A (en) 2011-04-29
ZA200707338B (en) 2011-10-26
AU2006214032A1 (en) 2006-08-24
US8461308B2 (en) 2013-06-11
RU2421466C2 (ru) 2011-06-20
US20110028696A1 (en) 2011-02-03
RU2007134662A (ru) 2009-03-27
US20090060908A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
NO20074063L (no) Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier
NO20073943L (no) Monoklonale antistoffer mot CD30 som mangler fukosylrester.
WO2007084672A3 (en) Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
UA92505C2 (ru) Композиции на основе антитела против cd3
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
MX2012012689A (es) Anticuerpos que tienen inmunogenicidad reducida en un ser humano.
WO2010031076A3 (en) Conversion of prenyl derivatives to isoprene
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
SG194465A1 (en) Novel immunoconjugates
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
MY160499A (en) Anti-cd38 antibodies
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
WO2008019148A3 (en) Tumor suppression using placental stem cells
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
AU2012328921A8 (en) Immunobinders directed against TNF
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
WO2019232409A9 (en) Methods for genome editing and activation of cells

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDAREX LLC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: E.R. SQUIBB & SONS, US

FC2A Withdrawal, rejection or dismissal of laid open patent application